TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23005030

Group type: EXPERIMENTAL
Intervention: Nonparametric Bayesian approach to estimate natural direct and indirect effects through a mediator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity parameters elicitation strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian approach applied to mediation assessment
Number of subjects: 0
Study: 18817993

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for initial 14 days after PCI and subsequent 30 mg/day during 6-month follow-up
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study: 17393542

Group type: EXPERIMENTAL
Intervention: Subthreshold depression in PD patients with dementia
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Male patients with subthreshold depression
Number of subjects: 538

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 538
Study: 16216739

Group type: EXPERIMENTAL
Intervention: Incision and drainage
Number of subjects: 45

Group type: COMPARATOR
Intervention: Needle aspiration
Number of subjects: 45
Study: 12392123

Group type: EXPERIMENTAL
Intervention: Model 1 (diagnostic model based on symptoms and gynaecological examination)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Model 2 (diagnostic model for identifying complete miscarriages)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: General practitioner clinical judgement
Number of subjects: 204
Study: 10433310

Group type: EXPERIMENTAL
Intervention: Rapid infusion of 100 mg/kg methotrexate (MTX) over 3 hours
Number of subjects: 29

Group type: COMPARATOR
Intervention: Regular infusion of 100 mg/kg methotrexate (MTX) over 6 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both rapid and regular infusion followed by irradiation
Number of subjects: 29
Study: 7776853

Group type: EXPERIMENTAL
Intervention: 3 MU lymphoblastoid interferon
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 MU lymphoblastoid interferon
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both doses (3 MU and 6 MU)
Number of subjects: 60
Study: 2323312

Group type: EXPERIMENTAL
Intervention: 1 mg oral naltrexone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous naloxone
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 662080

Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Methysergide (3 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg every 6 h for 7 days) followed by Metergoline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pimozide (1 mg every 6 h for 7 days) followed by Methysergide
Number of subjects: 34
Study: 31930993

Group type: EXPERIMENTAL
Intervention: Induction of labor at 39 weeks
Number of subjects: 6096

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 6096
Study: 31148146

Group type: EXPERIMENTAL
Intervention: Outpatient TLH (same-day discharge)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Inpatient TLH (overnight stay)
Number of subjects: 204
Study: 27480385

Group type: EXPERIMENTAL
Intervention: Pegylated asparaginase (PEG-ASP) 1000 IU/m2 administered on days 4 and 18 as part of a five-drug induction regimen
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PEG-ASP
Number of subjects: 90
Study: 26143022

Group type: EXPERIMENTAL
Intervention: synchronized Transcranial Magnetic Stimulation (sTMS)
Number of subjects: 202

Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: treatment-naïve subjects
Number of subjects: 202
Study: 22889694

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS‐MPH)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 21071617

Group type: EXPERIMENTAL
Intervention: Natural and temporally reordered musical stimuli
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural and temporally reordered speech stimuli
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heart rate variability and mean respiration rates
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temporal structure manipulation
Number of subjects: 20
Study: 18595749

Group type: EXPERIMENTAL
Intervention: Continuous infusion of intrathecal baclofen (CITB group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard treatment only (Control group)
Number of subjects: 17
Study: 17090232

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.3 mg.kg(‐1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nitrous oxide 30% in oxygen
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 35
Study: 14687010

Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy for 8 weeks (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Observation for 8 weeks followed by standardized physiotherapy (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy
Number of subjects: 50
Study: 11726429

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 70
Study: 9175978

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg-1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study: 7681289

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch with high C2/C6-substitution ratio (10.8)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Hydroxyethyl starch with low C2/C6-substitution ratio (5.8)
Number of subjects: 6
Study: 3632163

Group type: EXPERIMENTAL
Intervention: HBM clinical intervention in the ED
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HBM telephone call two days after the ED visit
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination clinical plus telephone intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 31939996

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) LVAD
Number of subjects: 1020

Group type: COMPARATOR
Intervention: HeartMate II (HMII) LVAD
Number of subjects: 1020
Study: 29974637

Group type: EXPERIMENTAL
Intervention: 1 nmol kg‐1 h‐1 kisspeptin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vehicle administration
Number of subjects: 15
Study: 27146116

Group type: EXPERIMENTAL
Intervention: Text messaging program combined with nicotine patches and gum, quitline referral, and SmokefreeTXT enrollment (4 weeks duration)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group received a brochure describing the state smokers' quitline
Number of subjects: 60
Study: 25603802

Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control stent
Number of subjects: 50
Study: 24074710

Group type: EXPERIMENTAL
Intervention: Fuzhenghuayu capsule (1.5 g, 3 times/day) with continued oral NAs (one tablet, 1 time/day) for 48 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Nucleos(t)ide analogs only for 48 weeks
Number of subjects: 110
Study: 20509823

Group type: EXPERIMENTAL
Intervention: 20 g fibre (fructose-oligosaccharides) diet supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: No fibre diet supplementation (control)
Number of subjects: 12
Study: 18417246

Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy (3 chemotherapy courses)
Number of subjects: 123
Study: 15629418

Group type: EXPERIMENTAL
Intervention: Preparation for Pain Management Intervention (2 sessions including assessment and feedback based on the PPMP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (treatment as usual and attention placebo interview)
Number of subjects: 78
Study: 12907818

Group type: EXPERIMENTAL
Intervention: Fugl‐Meyer arm scores of 11 points in the second week increasing to 19 points in the fourth week
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Motricity Index leg scores of at least 25 points in the first week
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Total anterior circulation infarcts, right hemisphere strokes, homonymous hemianopia, visual gaze deficit, visual inattention, and paresis
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Some dexterity in the paretic arm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Complete functional recovery
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No change in probabilities of prediction dexterity after 4 weeks
Number of subjects: 102
Study: 10751373

Group type: EXPERIMENTAL
Intervention: Brief intervention focusing on the uncontrollability of weight
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 8892458

Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 302

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 302
Study: 1993963

Group type: EXPERIMENTAL
Intervention: Dexamethasone, 0.5 mg/kg every 6 hours for a total of six doses, starting 6 to 12 hours before extubation.
Number of subjects: 153

Group type: COMPARATOR
Intervention: Saline solution (placebo).
Number of subjects: 153
Study: 6388012

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.d.)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30632410

Group type: EXPERIMENTAL
Intervention: Combined Atropine with Orthokeratology (AOK)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ortho-k alone (OK)
Number of subjects: 64
Study: 27177957

Group type: EXPERIMENTAL
Intervention: Bag extraction (study group, 76 patients)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard extraction without bag (control group, 80 patients)
Number of subjects: 156
Study: 26480304

Group type: EXPERIMENTAL
Intervention: Moisturizers containing formaldehyde (concentrations > 40, 20-40, 2.5-10 p.p.m.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moisturizers without formaldehyde
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (individuals without contact allergy to formaldehyde)
Number of subjects: 15
Study: 25140822

Group type: EXPERIMENTAL
Intervention: Nonlinear Pedagogy (manipulation of task constraints including equipment and rules)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Linear Pedagogy (prescriptive, repetitive drills)
Number of subjects: 24
Study: 23044180

Group type: EXPERIMENTAL
Intervention: Point of Care Technology (POCT) analysis
Number of subjects: 319

Group type: COMPARATOR
Intervention: Tube transporting for central laboratory analyses
Number of subjects: 319
Study: 18790598

Group type: EXPERIMENTAL
Intervention: Dexamphetamine 10mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17883739

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine with 2.5 microg/mL fentanyl
Number of subjects: 119

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 119

Group type: COMPARATOR
Intervention: 0.5% lidocaine
Number of subjects: 119
Study: 16087911

Group type: EXPERIMENTAL
Intervention: Gabapentin (900 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12065457

Group type: EXPERIMENTAL
Intervention: Norethisterone-enanthate (NET-EN) 200 mg, single intramuscular injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg, four injections every 6 weeks plus daily oral levonorgestrel (LNG, 250 microg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Norethisterone-enanthate (NET-EN), four injections every 6 weeks
Number of subjects: 42
Study: 10408822

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 34

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 34
Study: 7747232

Group type: EXPERIMENTAL
Intervention: Light normal activity intervention
Number of subjects: 975

Group type: COMPARATOR
Intervention: Control group (conventional medical treatment)
Number of subjects: 975
Study: 2291877

Group type: EXPERIMENTAL
Intervention: CGP 6140 (1200 mg single oral dose) after food intake
Number of subjects: 11

Group type: COMPARATOR
Intervention: CGP 6140 (1200 mg single oral dose) after an overnight fast
Number of subjects: 11
Study: 6271000

Group type: EXPERIMENTAL
Intervention: 15 g citrus pectin added to a mixed low fiber diet
Number of subjects: 8
Study: 31049873

Group type: EXPERIMENTAL
Intervention: Educational program delivered by pharmacists during three 30-min interviews over a 6-month period.
Number of subjects: 377

Group type: COMPARATOR
Intervention: No intervention (control group).
Number of subjects: 377
Study: 28719262

Group type: EXPERIMENTAL
Intervention: Mobile phone microscope
Number of subjects: 60
Study: 27301301

Group type: EXPERIMENTAL
Intervention: Ozone treatment for 60 seconds
Number of subjects: 138

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 138
Study: 24854218

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Intensive treatment-as-usual (TAU)
Number of subjects: 98
Study: 23175199

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 93
Study: 19279381

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB phototherapy combined with efalizumab (1 mg/kg body weight/week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Efalizumab monotherapy
Number of subjects: 10
Study: 17300358

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 15364353

Group type: EXPERIMENTAL
Intervention: Harmonic complex tones and the stem frequency tone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dichotic listening stimulation
Number of subjects: 12
Study: 11499329

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tretinoin 0.025% gel
Number of subjects: 143
Study: 9629935

Group type: EXPERIMENTAL
Intervention: Postoperative continuous epidural block combined with patient-controlled analgesia (PCA)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (suppositories or intramuscular injections of analgesics on request)
Number of subjects: 45
Study: 8117016

Group type: EXPERIMENTAL
Intervention: Suction drain and one conventional mediastinal drain (Group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional mediastinal drains (Group A)
Number of subjects: 180
Study: 3354801

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 1:200,000
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 40
Study: 15647870

Group type: EXPERIMENTAL
Intervention: magnesium/bisacodyl/picolax
Number of subjects: 176

Group type: COMPARATOR
Intervention: polyethylene glycol (PEG)/picolax
Number of subjects: 176
Study: 31088111

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 46
Study: 31545663

Group type: EXPERIMENTAL
Intervention: Romiplostim treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (untreated observation)
Number of subjects: 60
Study: 28146402

Group type: EXPERIMENTAL
Intervention: Corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Corticosteroid at 2 weeks after ACL injury, placebo at 4 days after ACL injury
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Corticosteroid at both time intervals
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo group (saline injections at both time intervals)
Number of subjects: 49
Study: 26700291

Group type: EXPERIMENTAL
Intervention: REACH-HF intervention plus usual care
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 216
Study: 23021708

Group type: EXPERIMENTAL
Intervention: SNPs identified in the discovery cohort
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cumulative SNP score model
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Cumulative SNP risk alleles
Number of subjects: 265
Study: 21262998

Group type: EXPERIMENTAL
Intervention: Losmapimod 7.5 mg twice daily for 28 days (n=27)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 56
Study: 18647203

Group type: EXPERIMENTAL
Intervention: Full-mouth periodontal debridement
Number of subjects: 25

Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing
Number of subjects: 25
Study: 16519625

Group type: EXPERIMENTAL
Intervention: Vitamin K1 10 mg per day injection intramuscularly or intravenously for 2‐7 days (n = 40)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment, n = 50)
Number of subjects: 90
Study: 16767907

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m2 over 30 minutes intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: FLEC (5-fluoruracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused bolus intra-arterially at three-weekly interval for 3 times)
Number of subjects: 138

Group type: COMPARATOR
Intervention: FLEC
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 138
Study: 10930202

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine (15 ml, 0.125%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no epidural catheter)
Number of subjects: 20
Study: 9460340

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone (80 mg/m2) with cytarabine (3 g/m2 daily for 5 days) and etoposide (150 mg/m2 for 3 days) in patients under 60 with AML.
Number of subjects: 136

Group type: COMPARATOR
Intervention: High-dose mitoxantrone with cytarabine as a single induction regimen in adults over 60 with untreated AML.
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High-dose mitoxantrone with cytarabine in previously untreated adults with ALL.
Number of subjects: 136
Study: 8105072

Group type: EXPERIMENTAL
Intervention: IVIG (400 mg per kilogram every 28 days)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 313
Study: 3812048

Group type: EXPERIMENTAL
Intervention: Inpatient treatment group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 17
Study: 28994192

Group type: EXPERIMENTAL
Intervention: Narrow-diameter implants (NDIs)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Regular-diameter implants (RDIs)
Number of subjects: 22
Study: 27196626

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clinical care only (Control)
Number of subjects: 27
Study: 25599119

Group type: EXPERIMENTAL
Intervention: Mothers And Daughters Exercising for Life (MADE4Life)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 88
Study: 23131199

Group type: EXPERIMENTAL
Intervention: Polyurethane foam (PUF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Polyvinyl acetate (PA)
Number of subjects: 52
Study: 20121893

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Post‐programme physical activity
Number of subjects: 16
Study: 18675269

Group type: EXPERIMENTAL
Intervention: Presence of a woman (informal contact for approximately 5 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of a woman
Number of subjects: 0
Study: 15885996

Group type: EXPERIMENTAL
Intervention: Endurance training (Group A, n=20)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Resistance training and callisthenics (Group B, n=22)
Number of subjects: 63
Study: 14503059

Group type: EXPERIMENTAL
Intervention: Xiaobai Mixture (XBM)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 8-MOP
Number of subjects: 74
Study: 11469290

Group type: EXPERIMENTAL
Intervention: 1.0 ml of Depo‐Medrol (40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.0 ml of sterile saline (control)
Number of subjects: 40
Study: 9351634

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) high dose: 1,540 microg per day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) low and medium doses: < 1,000 microg/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 8259628

Group type: EXPERIMENTAL
Intervention: 600 mg simethicone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3919804

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Multiple insulin injections
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 45
Study: 31432695

Group type: EXPERIMENTAL
Intervention: Glasdegib in combination with low-dose cytarabine (LDAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC)
Number of subjects: 0
Study: 29882961

Group type: EXPERIMENTAL
Intervention: 2 mg microdose of dextromethorphan (DM) administered orally with CYP2D6-dependent drugs
Number of subjects: 39

Group type: COMPARATOR
Intervention: 2 mg microdose of dextromethorphan (DM) administered orally without CYP2D6-dependent drugs
Number of subjects: 39
Study: 26973150

Group type: EXPERIMENTAL
Intervention: Family breakfast frequency
Number of subjects: 827
Study: 25168125

Group type: EXPERIMENTAL
Intervention: Oral antidiabetes agents (OADs)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: OAD plus glargine
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Basal bolus regimen
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Glargine alone
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Overall HbA1c change
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HbA1c <7%
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HbA1c 7-9%
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: HbA1c >9%
Number of subjects: 224

Group type: COMPARATOR
Intervention: Admission HbA1c ≤7%
Number of subjects: 224

Group type: COMPARATOR
Intervention: Admission HbA1c >7%
Number of subjects: 224
Study: 23139603

Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 561